Unlocking Potential

INCREASING THE VALUE OFBLOOD DONATIONS

BloodCenters

POTENTIAL CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. Together, we believe in the potential of blood to do even more for the world than it does today. This belief unites our organi-zation, inspires our innovation and strengthens our collaboration with customers to ultimately benefit the patients we all serve.

As we strive to make even safer, higher-quality transfusionsavailable to more people, we can unlock the potential of blood. We can help our customers bring even more treatment options to patients with advanced blood therapies. And we support researchers indeveloping cell therapies that may fundamentally improve health care. Terumo BCT is guided by our customers’ needs, aspirations and ongoing drive to improve efficiency and patient outcomes.

Terumo BCTUnlocking the potential of blood

AddINg vALUE AT EACh sTEP

dONOr mANAgEmENT

APhErEsIs COLLECTIONs

WhOLE BLOOd COLLECTIONs

PrOCEssINg

PAThOgEN rEdUCTION

dIvErsIfICATION

WOrkINg TOgEThEr

rEsEArCh COLLABOrATION

gLOBAL PrEsENCE

04

06

08

10

12

14

16

18

20

26

DONOR MANAGEMENTMatching each donor to bettercollection options

COLLECTIONSEnhancing efficiency and flexibility for in-center and mobile blood drives

PATHOGEN REDUCTIONWorking toward safer blood for patients,safe and simple procedures for operators

PROCESSINGImproving lab efficiency, blood componentquality and process control through automation

PATIENTNEEDS

COMPONENTDEMAND

AddINg vALUE AT EACh sTEP

Whatever your challenges—whether you are contending with the economic environment, adapting to changing demographics or expanding to meet new demand—Terumo BCT will work to deliver the advanced technologies, trustworthy advice and follow-through that only a truly committed partner can provide.

We help blood centers increase the value per donor at each step:

04 05

DONORMANAGEMENT

COLLECTIONS

PATHOGENREDUCTION

PROCESSING

PATIENTNEEDS

COMPONENTDEMAND

rEsPONdINg TO fUNdAmENTAL ChANgEs IN ThE dEmANd fOr BLOOd

WE hELP YOU WITh:

DonorMAX ProgramA donor-friendly kiosk, software system and recruitmentconsultation program to convert donors to give blood via apheresis, helping blood centers collect the components needed that day.

T-PODA software system that helps blood centers better determine donor procedure eligibility in the interview room, enablingoperators to collect better component combinations fromeach donor.

Productivity ToolsEducational resources to help support donor recruitmentand increase collections within blood centers.

Product and service availability varies by country.

Changing demographicsmany societies around the world are experiencing aging populations. As people age, they become less likely and ableto donate blood. In addition, older people are more likely to need blood transfusions, putting further strain on blood centers.

Shifting ethnicitiesIn certain geographies, ethnic shifts have caused an increase in the demand for blood types currently in short supply.This trend will likely continue in the coming years. Unfortunately, traditional outreach efforts struggle to recruit peoplewho can donate the types of blood that were once considered rare.

Now more than ever, it’s critical for blood centers to match each donor to better collection options. We help optimizecollections by developing new approaches, training staff and implementing new technologies that engage and educatedonors. Through these efforts, we help blood centers collect the components that reflect changing demand.

RIGHT DONOR +RIGHT PRODUCT+RIGHT TIME =MORE VALUE

06 07

DONORMANAGEMENT

COLLECTIONS(APHERESIS)

PATHOGENREDUCTION

PROCESSING

PATIENTNEEDS

COMPONENTDEMAND

INTEgrATINg IN-CENTEr ANd mOBILE BLOOd drIvEs

Vista® Information SystemA software system that helps blood centers proactively adapt to changing blood component demand by guiding collection efforts to make sure the right products are collected at the right time, from the right donor. via electronic recordkeeping ofeach collection, the system also helps blood centers improve regulatory compliance and reporting.

Trima Accel System ReporterA data transfer system that automatically records procedure data and easily uploads the information to a computer in a convenient, easy-to-understand format.

APhErEsIs sOLUTIONs

A range of solutions compatible with apheresis collections, including anticoagulant, platelet additive solution (PAs) andred cell storage solution.

Product and service availability varies by country.

WE hELP YOU WITh:

Trima Accel® Automated Blood Collection SystemThe world’s leading automated apheresis collection system enables blood centers to collect any blood component inany combination.

INfOrmATION TEChNOLOgY sYsTEms

Cadence Data Collection SystemA network device that enables our team of experiencedprofessionals to perform dynamic data analysis to helpblood centers improve operational efficiency.

Outcome ReviewA customizable analysis tool that helps blood centers identify additional collection opportunities, performance benchmarks and areas for potential increased efficiencies.

MORE COMPONENTS PER DONOR +MORE FREQUENT DONATIONS=MORE VALUE

At Terumo BCT, we believe in an integrated approach to apheresis collections. Donor education and qualification,collection technology and performance management systems work together as an efficient, automated solution.

This integrated approach has led to the wide adoption of our technology throughout the world. most importantly,we deliver the only apheresis system that can collect any blood component in any combination, uniquely positioningus to help you target specific component needs and quickly respond to any fluctuation in demand.

Our technology is already the global leader for in-center use and is gaining popularity for mobile drives. mobile donorsappreciate knowing they can give up to six times more platelets per donation compared to whole blood donations.Plus, they may be able to donate platelets nearly every other week, as compared to every other month with wholeblood donations. For blood centers, using a single technology in-center and for mobile drives creates greater efficienciesand enhances the value of each donation.

08 09

NN

G

DONORMANAGEMENT

COLLECTIONS(WHOLE BLOOD)

PATHOGENREDUCTION

PROCESSING

PATIENTNEEDS

COMPONENTDEMAND

DONOR COMFORT +IMPROVED LABORATORY EFFICIENCIES=MORE VALUE

rEsPECTINg ThE vALUE Of WhOLE BLOOd dONATIONs

TERUFLEX® blood bagsGives blood centers flexibility with a range of whole bloodcollection bags without leukocyte-reduction filters andmultiple bag configurations, collection volume options and anticoagulant/preservative combinations.

Atreus® Whole Blood Processing System disposablesdisposable collection sets aid automated whole bloodprocessing, complete with an organizer to facilitate moving, loading and unloading.

INfOrmATION TEChNOLOgY sYsTEms

TOMEsA multi-directional data management software that supports whole blood collection activities with the T-rAC-II.

AccessoriesTerumo BCT also offers a range of blood collection accessories and processing solutions.

Product and service availability varies by country.

WE hELP YOU WITh:

T-RAC-IIA system that helps standardize blood collections and can transfer supporting data via wireless or wired connections.

IMUFLEX® blood bag systems with in-line filtersflexible system of blood bags equipped with specialized leukocyte-reduction filters to meet your specific collection requirements:

• WB-SP—Produce three blood components: red blood cells, plasma and platelets

• WB-RP—Produce two blood components: red blood cells and plasma

• Red Cell Filter—Produce plasma, platelet concentrate and red cell concentrate

• Collection Line—Equipped with a needle protector and sampling system for added safety

Each unit of whole blood can help multiple patients, so it is essential that the process and products used to collectblood respect the inherent value of every donation. We have understood and supported these all-important bloodcollections for more than 40 years, with a diverse range of reliable, innovative products.

Not only do our collection products and accessories meet high standards for quality and safety today, our innovationpipeline will remain focused on enhancing donor comfort and increasing efficiencies within component laboratories.for example, we are introducing the use of whole blood collection bags that are compatible with automated processingto help lower costs and risks.

10 11

DONORMANAGEMENT

COLLECTIONS

PATHOGENREDUCTION

PROCESSING

PATIENTNEEDS

COMPONENTDEMAND

PrOvIdINg A CLEAr PATh TO AUTOmATEd BLOOd PrOCEssINg

TSCD® II, TSCD® and SCD®-II B Sterile Tube WeldersWhile maintaining a functionally closed system, these devices create strong and consistent sterile welds for your docking requirements.

INfOrmATION TEChNOLOgY sYsTEms

Atreus System ManagerWorks with the Atreus system to improve process control,regulatory compliance and management reports.

Cadence Data Collection SystemA network device that enables our team of experiencedprofessionals to perform dynamic data analysis to help blood centers improve operational efficiency.

TOMEsA multi-directional data management solution to support whole blood collection activities with the T-rAC-II.

Product and service availability varies by country.

WE hELP YOU WITh:

Atreus systemThe first system to automate the steps of wholeblood processing.

TACSI® Terumo Automated Centrifugeand Separator IntegrationAn automated Buffy Coat processor that improves efficiencyby processing six pooled units at a time.

OrbiSac SystemThe first system to merge the manual steps involvedin Buffy Coat platelet and pooling processing into oneautomated procedure.

T-ACE II+This flexible automated blood component expressor brings a high degree of flexibility to automated component separation

T-SEAL-II and Teruseal® Tube Sealersversatile table top technologies that produce reliable,quality seals that are easy to separate.

AUTOMATED COMPONENT PROCESSING +AUTOMATED COMPLIANCE SUPPORT+AUTOMATED DATA MANAGEMENT=MORE VALUE

Making the transition from manual to automated whole blood processing can greatly improve efficiency,blood product quality and process control.

As a trusted partner, Terumo BCT is here to help you make that transition. Our systems automate mostmanual processing steps and we have the knowledge and experience to improve your entire whole blood process.

A clear path to automated processingmaking the change from manual to automated processing might seem out of reach. Terumo BCT works closelywith customers around the world to establish and share best practices. Through this collaboration, we help blood centers achieve the benefits of automated whole blood processing.

12 13

DONORMANAGEMENT

COLLECTIONS

PATHOGENREDUCTION

PROCESSING

PATIENTNEEDS

COMPONENTDEMAND

rEALIZINg ThE POTENTIALOf PAThOgEN rEdUCTION

WE hELP YOU WITh:

Mirasol® Pathogen Reduction Technology SystemInnovative technology using riboflavin and ultraviolet light to inactivate residual white blood cells and reduce the level of known and unknown pathogens before blood products are transfused.

Mirasol® ManagerIntegrates with the system to capture and store data to help ensure accurate reporting and simplified data management.

Product and service availability varies by country.

SAFETY FOR OPERATORS+EFFECTIVE PATHOGEN TREATMENT+SIMPLICITY OF ONE PLATFORM=MORE VALUE

few technologies have the potential to improve blood safety the way our mirasol® Pathogen reductionTechnology system does. The technology inactivates residual white blood cells and reduces the levelof known and unknown pathogens. It is designed to be safe and simple for operators.

The Mirasol system uses riboflavin (vitamin B2), a naturally occurring, non-toxic compound and ultraviolet lightto work toward safer blood for patients. The system is also a model of efficiency, with a single platform for treatingplatelets and plasma today, and, potentially, whole blood in the future.

14 15

Growing in new directionsAt Terumo BCT, not only are we committed to adding valueto your current operations, we can also help you expand into new areas.

Therapeutic apheresis In many locations around the world, plasmapheresis,cytapheresis and red blood cell exchange are expanding the number of treatment options for patients. These treatments are being applied in freestanding clinics, dedicated therapeutic apheresis centers or in conjunction with local hospitals. Cell therapyCell therapies have the potential to fundamentally change the way many diseases are treated. Blood cells collected from as little as 25 mL of bone marrow can be expanded into hundreds of millions of cells.

Terumo BCT provides the right tools to help you effectively implement a cell therapy program that complements existing services while you achieve new levels of patient care. regardless of the development path you pursue, we can support your center with a scalable solution to help advance your effortsto move from the laboratory, to clinical trial and ultimatelycommercial availability.

dIvErsIfICATION

HELPING BLOODCENTERS DIVERSIFY

WE hELP YOU WITh:

Spectra Optia® Apheresis SystemA flexible system that helps produce reliable therapeuticapheresis results across a wide range of operator skills and patient conditions.

Elutra® Cell Separation SystemThe world’s first functionally closed system for monocyteenrichment.

COBE® 2991 Cell ProcessorA versatile, reliable system for multiple cell processingprocedures, with automation to help ensure repeatable results.

Quantum® Cell Expansion SystemA functionally closed, hollow-fiber bioreactor system that streamlines cell expansion through a reproducible, scalable automated process.

Product and service availability varies by country.

16 17

Each and every exchange we have with our customers isimportant. By fostering open and ongoing relationships,we bring more value to you, our industry and ultimately the patients we’re all focused on serving.

By actively listening, we can develop technologies to better meet your specific needs. Even after a technology is in place, we continue to serve you with comprehensive technical and operator training, responsive support, and flexible serviceoptions to help prevent and resolve issues.

Education and trainingOur programs provide your operators and technicians with theknowledge and confidence they need in the most convenientway possible. Basic or advanced, in-person or online, yourfacility or ours, instructor-led or self-paced—our wide rangeof learning options strive to meet your specific requirements.

Clinical and technical supportDay after day and year after year, our experienced team isresponsive to your needs. We provide implementation support, investigative problem-solving and specialized software support. By helping integrate information technology system, we can improve the flow of data. We can even remotely monitor various technologies to help improve their performance. We also offer multiple service plans to meet your specific needs.

Sharing insightsWe believe in sharing information and experiences, and weencourage our customers to do the same. By applying customer experiences from around the world, we can help simplify how you adopt our technology, measure performance for improved accuracy, improve existing operations and expand into newareas. We also leverage the invaluable insight and feedback from our customers to help shape existing technologies and upcoming innovations.

Knowledge centerThis dynamic online resource enables you to access technical and clinical information helpful in operating and maintaining our systems. With a few clicks, you can easily find education and training materials, operator manuals, quick reference guides, scientific literature, clinical white papers and much more.

WOrkINg TOgEThEr

INNOVATIONS THAT UNLOCK POTENTIAL CAN ONLY BE REALIZED THROUGH COLLABORATION

18 19

BY ACCELErATINg rEsEArCh, WE CAN sPEEd UP INNOvATION, mAkE ITmOrE rELEvANT ANd UNLOCk ThEPOTENTIAL Of BLOOd

20 21

ThE rOLE Of rEsEArChhealth care advancements depend on research to identify issues and objectively evaluate potential solutions. With these findings in mind, new innovations can be developed and ultimately brought to health care practitioners to move health care forward.

RESEARCH

INNOVATION

INSIGHT

rEsEArCh IdENTIfIEs NEEds ANd PrOvEs Or dIsPrOvEs ThE vALUE Of NEW APPrOAChEs

INNOvATION TrANsLATEs INsIghTs INTO sOLUTIONs ThAT WOrk IN PrACTICE

shArEd INsIghT CrEATEs WIdEr dEmANd fOr ImPrOvEmENTs

22 23

At Terumo BCT, we recognize the need for both basic and applied research and aspire to expand our efforts.To help accelerate research, we invest in applied research projects around the world and make our technologiesand expertise readily available. The insights generated by these research efforts can create a wider demand forproduct improvements and enable us to innovate new technologies, bringing them to market sooner.

Not all products currently available in all countries.

rEsEArCh COLLABOrATION

AUSTRALIA, EUROPE AND NORTH AMERICA PLAsmA EXChANgE IN ANCA-AssOCIATEd vAsCULITIs

FRANCE AND GERMANYsTEm CELL EXPANsION

DENMARKPrEss TrIAL

ITALYIPTAs CLINICAL TrIAL

FRANCEhEPATITIs C rEdUCTION TrIAL

UNITED STATESdONOr CONvErsION TrIAL

FRANCEPLAsmAsEP TrIAL

UNITED STATESPAThOgEN rEdUCTION sTUdY

A 500-patient study conducted in collaboration with 100 institutions around the world including the European Vasculitis Study Group and the Vasculitis Clinical Research Consortium. Supported in conjunction with the U.S. National Institutes of Health, U.S. Food and Drug Administration, Canadian Institutes of Health Research, United Kingdom National Institute for Health Research, Australian Department of Health and Fresenius Medical Care.

OBJECTIVEEvaluate the efficacy of therapeutic plasma exchange and the safe reduction of Glucocorticoid dosing to treat severe vasculitis where antineutrophilcytoplasmic antibodies (ANCAs) are detected.

Collaboration with the CASCADE Consortium.

OBJECTIVEDevelop standardized GMP methods for culturing/expanding adult mesenchymal stem cells for research and clinical applications.

Supporting a 40-patient study conducted in collaboration with Rigshospitalet–Copenhagen University Hospital.

OBJECTIVEEvaluate the viability of Mirasol-treated platelets stored in plateletadditive solution for seven days.

Supporting an 800-patient study conducted in collaboration with theItalian National Institute of Transfusion Medicine.

OBJECTIVEEvaluate the clinical effectiveness of Mirasol-treated platelets in plasmaand test the possibility of preventing alloimmunization reactions inpatients who receive multiple transfusions.

Supporting in vitro studies with University Hospital of Amiens.

OBJECTIVEEvaluate the effectiveness of the Mirasol Pathogen ReductionTechnology System on the hepatitis C virus.

Developing methods for reducing the infectious pathogen load in bloodproducts with the support of the U.S. Department of Defense (DoD).This includes in vitro work evaluating pathogen kill levels, cell and proteinquality, blood product functionality and in vivo studies in human subjects.In 2010, an in vivo feasibility study under a Food and Drug Administration Investigational Device Exemption was completed as part of thisprogram with funding from the DoD.

OBJECTIVEEvaluate the efficacy of the Mirasol system in providing safer and more effective blood for patients who experience life-threatening blood loss.

Supporting a five-month trial in collaboration with United Blood Servicesof Louisiana.

OBJECTIVEEvaluate the effectiveness of the DonorMAX program to convert people from donating whole blood to apheresis collections.

Supporting a prospective 80-patient, double-blind placebo-controlled study in collaboration with University Hospital, Bordeaux, France.

OBJECTIVEEvaluate the efficacy of therapeutic plasma exchange on MultipleSclerosis patients who experience relapses without improvementafter steroid treatment.

With more than 2,500 associates in 30 countries, Terumo BCT is closely connected to our customers around the world. We achieve a lot by working closely with customers, and our team of highly-skilled specialists continually builds these relationships. We support thousands of systems in over 90 countries and the average relationship with our customersspans more than 20 years. Terumo BCT also has long-lasting relationships with influential industry organizations such asthe AABB, the Advanced medical Technology Association, AsfA, Eucomed, the International society of Blood Transfusion,the National Blood foundation and many others throughout the world.

TO LEARN MORE, VISIT WWW.TERUMOBCT.COM

OUr gLOBAL PrEsENCE mAkEs PArTNErshIP POssIBLE

22

CaridianBCT, Inc.10811 West Collins AvenueLakewood, Colorado 80215-4440UsA

UsA Phone: 1.877.339.4228Phone: +1.303.231.4357fax: +1.303.542.5215

CaridianBCT Europe N.V.Europe, middle East and AfricaIkaroslaan 411930 ZaventemBelgium

Phone: +32.2.715.05.90fax: +32.2.721.07.70

CaridianBCT (Asia Pacific) Ltd.room 3903-3903A, 39/fNew York Life Tower, Windsor house311 gloucester roadCauseway Bay, hong kong

Phone: +852.2283.0700fax: +852.2576.1311

CaridianBCT Latin AmericaJuncal 1311 4th floorC1062ABOBuenos AiresArgentina

Phone: +54.11.5530.5200fax: +54.11.5530.5201

CaridianBCT and Terumo Transfusion are becoming Terumo BCT, the world leader in blood component technology. Our products and services are designed to set new levels of performance today, and our innovation pipeline strives to substantially improve blood collection and processing, blood therapies and the development of cell therapies in the years ahead.

TERUMO BCTUNLOCKING THE POTENTIAL OF BLOOD

TERUMOBCT.COM ©2

011

Car

idia

nB

CT,

Inc.

/ P

N 3

06

62

0-1

60